Nab-Rapamycin
Desmoid Tumor
Sarcoma Oncology Research Center, LLCUNKNOWNPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Desmoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Parabilis Medicines, Inc. | Phase 2 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Trifluridine Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Tipiracil Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Fog-001 Parabilis Medicines, Inc. | Phase 1/2 | CCC |
Tegavivint Children's Oncology Group | Phase 1/2 | CCC |
N-Desmethyl-4-Hydroxytamoxifen National Cancer Institute (NCI) | Phase 1 | CC |
Fes F-18 Vanderbilt-Ingram Cancer Center | Early Phase 1 | C |
Same molecule, other indications
Nab-Rapamycin is also rated in:
neoplasm with perivascular epithelioid cell differentiationDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →